Expansion of Ardena development and manufacturing site to aid in COVID-19 vaccine development by Novavax
Pharmaceutical CDMO Ardena (Gent, Belgium) announce the expansion of its capacity for purification and fractionation at its site in Södertälje (Sweden) to aid Novavax (MD, USA) in the long-term production of their COVID-19 vaccine.
Following conditional marketing authorization granted by the European Commission, Novavax’s COVID-19 vaccine, termed Nuvaxovid, will be the fifth vaccine approved for utilization in Europe. As a recombinant protein-based vaccine, Ardena’s expansion will satisfy Novavax’s demand for chromatographic capabilities, tangential flow filtration and lyphilization capabilities. Ardena has been a partner of Novavax for 15 years for the development of a fractionation process for Matrix-M™, a key adjuvant in Nuvaxovid to enhance immune response against the SARS-CoV-2 virus.
